Pro-DEX (NASDAQ: PDEX) revenue
Pro-DEX reported revenue of $77.5m for fiscal 2026, 16.5% more than in fiscal 2025 ($66.6m). Since fiscal 2017 its revenue has grown by 253.4%, an average growth of 15.1% a year.
Pro-DEX has grown its revenue for 9 years in a row, and fiscal 2026 is the highest of its 10 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2026 | $77.5m | +16.5% | $13.0m | 16.8% |
| 2025 | $66.6m | +23.7% | $10.7m | 16.1% |
| 2024 | $53.8m | +16.8% | $7.2m | 13.3% |
| 2023 | $46.1m | +9.6% | $5.8m | 12.5% |
| 2022 | $42.0m | +10.5% | $5.1m | 12.2% |
| 2021 | $38.0m | +9.2% | $4.5m | 11.9% |
| 2020 | $34.8m | +28.2% | $7.1m | 20.3% |
| 2019 | $27.2m | +21.0% | $5.0m | 18.4% |
| 2018 | $22.5m | +2.4% | $2.4m | 10.6% |
| 2017 | $21.9m | — | $2.7m | 12.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Pro-DEX revenue compared with its sector
By revenue for its latest fiscal year, Pro-DEX ranks 304th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Pro-DEX, 16.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 302nd | ETON Pharmaceuticals | $80.0m | 104.9% |
| 303rd | Simulations Plus | $79.2m | 13.1% |
| 304th | Pro-DEX | $77.5m | 16.5% |
| 305th | Sight Sciences | $77.4m | −3.1% |
| 306th | CytomX Therapeutics | $76.2m | −44.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Pro-DEX
- How much revenue did Pro-DEX make in fiscal 2026?
- Pro-DEX reported revenue of $77.5m for fiscal 2026, compared with $66.6m in fiscal 2025.
- How much has the revenue of Pro-DEX grown?
- Between fiscal 2017 and fiscal 2026 it went from $21.9m to $77.5m: 253.4% more, an average growth of 15.1% a year.
- What was the best year for revenue at Pro-DEX?
- Of its last 10 fiscal years, fiscal 2026, with $77.5m.
- Where does Pro-DEX rank in its sector by revenue?
- It ranks 304th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Pro-DEX come from?
- From the annual report (Form 10-K) that Pro-DEX files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Pro-DEX files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Pro-DEX: the Pro-DEX page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.